XL999

Overview

XL999 has the potential to provide benefit to patients with lung cancer and acute myelogenous leukemia. XL999 is a new chemical entity that inhibits a spectrum of receptor tyrosine kinases (RTKs) with growth promoting and angiogenic properties, including FGFR 1/3, PDGFRα/β, VEGFR2/KDR, KIT, and FLT3. XL999 also inhibits FLT4 and SRC. XL999 has the potential to prevent tumor growth — both directly by a novel effect on tumor cell proliferation and indirectly through inhibition of the host angiogenic response. XL999 induces a cell-cycle block by a mechanism distinct from those previously identified and exhibits broad antitumor activity in xenograft models.

Indication

Investigated for use/treatment in cancer/tumors (unspecified), lung cancer, and solid tumors.

Associated Conditions

No associated conditions information available.

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
XL999 Administered Intravenously to a Subject With Advanced Malignancies	2013/09/18	NCT01945164	N/A	NO_LONGER_AVAILABLE	John Sarantopoulos
Maintenance Study on the Long Term Safety of XL999	2009/08/07	NCT00955084	Phase 1	Completed	Symphony Evolution, Inc.
Safety Study of XL999 in Adults With Non-Small-Cell Lung Cancer	2007/06/26	NCT00491699	Phase 1	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Acute Myeloid Leukemia (AML)	2006/05/08	NCT00322673	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Multiple Myeloma	2006/03/20	NCT00304590	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Previously Treated Ovarian Cancer	2006/01/16	NCT00277290	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Non-small Cell Lung Cancer	2006/01/16	NCT00277329	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Metastatic Colorectal Cancer	2006/01/16	NCT00277303	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Patients With Metastatic Renal Cell Carcinoma	2006/01/16	NCT00277316	Phase 2	Terminated	Symphony Evolution, Inc.
Study of XL999 in Adults With Solid Tumors	2005/02/24	NCT00104117	Phase 1	Completed	Symphony Evolution, Inc.

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

AI-Powered Research

Premium Access